Physician profile
Patrick L Mcginnis
NPI 1174678684
$256.17
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $33.86 · 2022: $101.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $121.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.28 | 2022 | |
| Merck Sharp & Dohme LLC | $40.73 | 2022 | |
| Seagen INC. | $17.29 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 2020 | |
| Celgene Corporation | $13.70 | 2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcginnis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.